Adefovir (Hepsera) for Chronic Hepatitis B Infection
Adefovir dipivoxil (Hepsera - Gilead), a nucleotide analog, has been approved by the FDA for oral treatment of chronic active infection with hepatitis B virus (HBV). In 1999, because of concerns about renal toxicity, the FDA rejected a higher-dosage formulation of adefovir for treatment of HIV infection....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Adefovir (Hepsera) for Chronic Hepatitis B Infection
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1145
Article Code: 1145b
Date: December 9, 2002
Volume: 44
Pages: 105-106
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1145
Article Code: 1145b
Date: December 9, 2002
Volume: 44
Pages: 105-106
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)